cas 2438241-40-6|| where to buy 3-(5,6-difluoro-1-oxo-isoindolin-2-yl)piperidine-2,6-dione

Produktname:3-(5,6-difluoro-1-oxo-isoindolin-2-yl)piperidine-2,6-dione

IUPAC Name:3-(5,6-difluoro-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

: CAS：2438241-40-6; Molekulare Formel：C13H10F2N2O3; Reinheit：97%

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM1077103-100mg	in stock	ȖȅŪ
CM1077103-250mg	in stock	Ūȅȯ
CM1077103-500mg	in stock	ǫŞǫ
CM1077103-1g	in stock	ȯȅȯ
CM1077103-5g	in stock	ȖƃŪƥ
CM1077103-10g	in stock	Ūƛǫƥ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2438241-40-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2438241-40-6; Molekulare Formel:C13H10F2N2O3; Schmelzpunkt:-; SMILES-Code:FC1=C(F)C=C2C(CN(C3CCC(=O)NC3=O)C2=O)=C1; Dichte:

: Katalognummer:CM1077103; Molekulargewicht:280.23; Siedepunkt:; Mdl-Nr.:; Lagerung:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.